ADI-PEG20 Phase 3 Trial Shows Promise: ATOMIC-Meso Results
ATOMIC-Meso Phase 3 trial shows ADI-PEG20 plus chemotherapy improves survival in pleural mesothelioma. Analysis of this arginine-depleting therapy.
News & Research
104 articles
Latest mesothelioma updates and data-driven research from peer-reviewed sources
Latest News
research TEAD Inhibitor IK-930 Shows Activity in Mesothelioma: ESMO Update
research UV1 Cancer Vaccine Receives FDA Fast Track for Mesothelioma
news 93 Clinical Trials Are Recruiting Mesothelioma Patients Right Now. Here's What's Being Tested.
news The Asbestos Cover-Up: What the Industry Knew in 1930
exposure Your Mechanic May Be Breathing Asbestos Right Now
news 3,000 Americans Die From Mesothelioma Yearly
exposure The Hidden Danger in Your Ceiling
exposure Advocates Sue for East Wing Asbestos Records
research New Review Maps BAP1 Loss in Mesothelioma
exposure UK Recalls Children's Play Sand After Asbestos Found
news UK, EU Split on Talc Cancer Classification
legal Mesothelioma Lawsuit: $42.6M J&J Verdict — MesoWatch
exposure Montana Windstorm Scatters School Asbestos
BREAKING Cell Therapy Shrinks Tumors in 63%
exposure Cassiar: The Town That Asbestos Built
legal Vi-Jon Talc Mesothelioma Trial in California
exposure Cold Lake School Closes After Asbestos Found
asbestos Malaysia Asbestos Ban Push Intensifies
legal J&J Talc Verdicts Top $2.5B in 2025
news Mesothelioma Treatment Advances: 2025
BREAKING Record $1.56B Verdict Against J&J in Talc
legal $65.5M J&J Talc Verdict in Minnesota
legal Talc Lawsuit: $40M J&J Verdict, Ovarian Cancer — MesoWatch
research Drug Combo Achieves 60% Response Rate
news FDA Withdraws Talc Asbestos Testing Rule
treatment One Drug Halted, Another Advances
exposure Asbestos in Children's Art Sand: Australia
legal Judge Allows Experts in 67,500 Talc Cases
exposure Japan Banned Asbestos in 2006, Cases Rise
legal Mesothelioma Lawsuit: $20M J&J Florida Verdict — MesoWatch
exposure Minot AFB Missile Crews Face Asbestos Risk
research Mesothelioma Survival: 18-Year Survivor's Story — MesoWatch
legal $966M Verdict: J&J Liable for Talc Death
news Mesothelioma Awareness Day: September 26
research Mesothelioma Treatment: Hopkins Immunotherapy Trial — MesoWatch
treatment VT3989 Doubles Time Without Progression
clinical-trials Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch
treatment Hopkins: Pre-Surgery Immunotherapy Success
treatment Trial Tests Immunotherapy Before Surgery
research IMPALA Trial: Light Therapy for Mesothelioma
exposure Paramount Studios Faces Asbestos Suits
clinical-trials Nivolumab + Ipilimumab Trial for Pleural Mesothelioma — MesoWatch
clinical-trials CAR-T Trial: Phase 1 Study for Mesothelioma — MesoWatch
news Asbestos Disclosure Bill H.R.4247
exposure Libby, Montana: America's Deadliest Town
treatment Dual-Target Immunotherapy Shows 52% Response
news UK Commits £1.2B for Asbestos Removal
exposure UK Has World's Highest Meso Rates
exposure Canada Banned Asbestos, Cases Still Rise
treatment FDA Approves Opdivo Qvantig for Mesothelioma
exposure Utah Windstorm Spreads Mine Asbestos
clinical-trials Nivolumab + Ipilimumab Phase 2 Trial for Mesothelioma — MesoWatch
treatment KEYNOTE-483: Keytruda Combo Approved
clinical-trials Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch
news 9/11 Mesothelioma Crisis Still Unfolding
clinical-trials Nivolumab + Ipilimumab Phase 1 Trial for Mesothelioma — MesoWatch
research DENIM Trial: Vaccine Did Not Extend Survival
exposure WHO Classifies Talc as Probable Carcinogen
clinical-trials Immunotherapy Trial: Phase 1 Study for Mesothelioma — MesoWatch
clinical-trials Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch
clinical-trials CAR-T Trial: Phase 1 Study for Pleural Mesothelioma — MesoWatch
research MARS 2: Chemo Outperformed Surgery
clinical-trials CAR-T Trial: Phase 1 Study for Mesothelioma — MesoWatch
exposure EPA Bans Chrysotile: First U.S. Asbestos Ban
clinical-trials Pembrolizumab Phase 2 Trial for Pleural Mesothelioma — MesoWatch
clinical-trials CAR-T Trial: Phase 1 Study for Mesothelioma — MesoWatch
treatment ATOMIC-Meso: Quadrupled 3-Year Survival
treatment CONFIRM Trial: Nivolumab Extends Survival
news 2023 Mesothelioma Verdicts: $40M+ Awards
clinical-trials Nivolumab + Ipilimumab Trial for Pleural Mesothelioma — MesoWatch
clinical-trials Nivolumab + Ipilimumab Trial: Study for Mesothelioma — MesoWatch
clinical-trials HIPEC Trial: Phase 2 Study for Peritoneal Mesothelioma — MesoWatch
news Court Rejects J&J's 2nd Talc Bankruptcy
clinical-trials Atezolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch
treatment SynKIR-110 CAR-T Gets FDA Fast-Track
clinical-trials Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch
exposure J&J Discontinues Talc Baby Powder
clinical-trials Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch
clinical-trials Atezolizumab Phase 1 Trial for Pleural Mesothelioma — MesoWatch
clinical-trials Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch
clinical-trials Nivolumab + Ipilimumab Trial for Pleural Mesothelioma — MesoWatch
news EPA Proposes Chrysotile Asbestos Ban
clinical-trials HIPEC Trial: Phase 2 Study for Peritoneal Mesothelioma — MesoWatch
clinical-trials Atezolizumab Phase 3 Trial for Pleural Mesothelioma — MesoWatch
clinical-trials CAR-T Trial: Study for Mesothelioma — MesoWatch
clinical-trials HIPEC Trial: Phase 1 Study for Peritoneal Mesothelioma — MesoWatch
news J&J Creates LTL to Shield Talc Liability
legal J&J's Texas Two-Step: 3 Failed Attempts
clinical-trials Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch
clinical-trials Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch
clinical-trials Nivolumab + Ipilimumab Phase 1 Trial for Mesothelioma — MesoWatch
news FDA OKs Opdivo+Yervoy for Mesothelioma
treatment CheckMate-743: Immunotherapy Beats Chemo
legal Jury Awards $750M to 4 Meso Patients
clinical-trials Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch
exposure FDA Finds Asbestos in J&J Baby Powder
news FDA Approves Optune Lua for Mesothelioma
exposure FDA Finds Asbestos in Claire's Makeup
legal St. Louis Jury Awards $4.69B in Talc Case
clinical-trials Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch
exposure Brazil Bans Asbestos in Landmark 2017 Ruling
exposure Lautenberg Act: Path to Asbestos Ban
news Zadroga Act: Permanent Care for 9/11 Responders
Featured Coverage
In-depth reporting, data analysis, and investigations
DATA
Talcum Powder Crisis By the Numbers
The talc crisis by the numbers: 90,000+ lawsuits, $10B+ in verdicts, and decades of corporate knowledge. The data tells the story.